S
S. Rod Rassekh
Researcher at University of British Columbia
Publications - 27
Citations - 1114
S. Rod Rassekh is an academic researcher from University of British Columbia. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 12, co-authored 27 publications receiving 895 citations. Previous affiliations of S. Rod Rassekh include Boston Children's Hospital & Yokohama City University.
Papers
More filters
Journal ArticleDOI
Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
Henk Visscher,Colin J. D. Ross,S. Rod Rassekh,Amina Barhdadi,Marie-Pierre Dubé,Hesham Al-Saloos,George S. Sandor,Huib N. Caron,Elvira C. van Dalen,Leontien C. M. Kremer,Helena J H van der Pal,Andrew M.K. Brown,Paul Rogers,Michael S. Phillips,Michael J. Rieder,Bruce Carleton,Michael R. Hayden +16 more
TL;DR: Combining multiple variants into a single-prediction model together with clinical risk factors and classification of patients into three risk groups identified multiple genetic variants in SLC28A3 and other genes associated with ACT.
Journal ArticleDOI
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Colin J. D. Ross,Colin J. D. Ross,Hagit Katzov-Eckert,Hagit Katzov-Eckert,Marie-Pierre Dubé,Beth Brooks,S. Rod Rassekh,Amina Barhdadi,Yassamin Feroz-Zada,Henk Visscher,Henk Visscher,Andrew M.K. Brown,Michael J. Rieder,Paul Rogers,Michael S. Phillips,Bruce Carleton,Bruce Carleton,Michael R. Hayden,Michael R. Hayden +18 more
TL;DR: Association analyses for 220 drug-metabolism genes in genetic susceptibility to cisplatin-induced hearing loss in children are reported and genetic variants in TPMT and COMT are identified associated with cisPlatin- induced hearing Loss in children.
Journal ArticleDOI
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.
Janessa Laskin,Steven J.M. Jones,Samuel Aparicio,Stephen Chia,Carolyn Ch'ng,Rebecca J. Deyell,Peter Eirew,Alexandra Fok,Karen A. Gelmon,Cheryl Ho,David G. Huntsman,David G. Huntsman,Martin L. Jones,Katayoon Kasaian,Aly Karsan,Sreeja Leelakumari,Yvonne Y. Li,Howard John Lim,Yussanne Ma,Colin Mar,Monty Martin,Richard D. Moore,Andrew J. Mungall,Karen Mungall,Erin Pleasance,S. Rod Rassekh,Daniel J. Renouf,Yaoqing Shen,Jacqueline E. Schein,Kasmintan A. Schrader,Sophie Sun,Anna V. Tinker,Eric Y. Zhao,Stephen Yip,Marco A. Marra +34 more
TL;DR: The experience indicates that a multidisciplinary team of clinicians and scientists can implement a paradigm in which whole-genome analysis is integrated into the care of late stage cancer patients to inform systemic therapy decisions.
Journal ArticleDOI
Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.
Henk Visscher,S. Rod Rassekh,George S. Sandor,Huib N. Caron,Elvira C. van Dalen,Leontien C. M. Kremer,Helena J.H. van der Pal,Paul Rogers,Michael J. Rieder,Bruce Carleton,Michael R. Hayden,Colin J. D. Ross +11 more
TL;DR: Two novel variants in SLC 22A17 and SLC22A7 were significantly associated with anthracycline-induced cardiotoxicity and improved a genotype-guided risk prediction model, which could improve patient risk stratification.
Journal ArticleDOI
Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR.
Miguel Alcaide,Matthew C. Cheung,Jack Hillman,S. Rod Rassekh,Rebecca J. Deyell,Gerald Batist,Aly Karsan,Alexander W. Wyatt,Nathalie A. Johnson,David W. Scott,Ryan D. Morin +10 more
TL;DR: The assay described herein is a powerful tool to establish quality controls and stratify cfDNA samples based on presumed ctDNA levels, then facilitating the implementation of robust, cost-effective and standardized analytical workflows into clinical practice.